Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates
Joint Authors
Kamar, Nassim
Rostaing, Lionel
Mehawej, Mireille
Alric, Laurent
Del Bello, Arnaud
Izopet, Jacques
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-07-16
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background.
There are few data on the combination of (pegylated-) interferon- (Peg-IFN-) α, ribavirin, and first-generation direct-acting antiviral agents (DAAs).
Our aim was to describe the efficacy and safety of Peg-IFN-α, ribavirin, and boceprevir in hemodialysis patients.
Patients.
Six hemodialysis patients, chronically infected by genotype-1 HCV, were given Peg-IFN-α (135 µg/week), ribavirin (200 mg/d), and boceprevir (2400 mg/d) for 48 weeks.
Results.
At initiation of antiviral therapy, median viral concentration was 5.68 (3.78–6.55) log IU/mL.
HCV RNA was undetectable in four of the six patients at week 4 and in all patients at week 24.
A breakthrough was observed in two patients between weeks 24 and 48, and a third patient stopped antiviral therapy between weeks 24 and 48 because of severe peripheral neuropathy.
At week 48, HCV RNA was undetectable in three patients.
Of these, two patients relapsed within a month after antiviral therapy was stopped.
Hence, only one patient had a sustained virological response; he was a previous partial responder.
Overall, anemia was the main side effect.
Conclusion.
A triple antiviral therapy based on Peg-IFN-α, ribavirin, and boceprevir is not optimal at treating hemodialysis patients with chronic HCV infection.
Studies using new-generation drugs are required in this setting.
American Psychological Association (APA)
Mehawej, Mireille& Rostaing, Lionel& Alric, Laurent& Del Bello, Arnaud& Izopet, Jacques& Kamar, Nassim. 2015. Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of Transplantation،Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1070432
Modern Language Association (MLA)
Mehawej, Mireille…[et al.]. Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of Transplantation No. 2015 (2015), pp.1-5.
https://search.emarefa.net/detail/BIM-1070432
American Medical Association (AMA)
Mehawej, Mireille& Rostaing, Lionel& Alric, Laurent& Del Bello, Arnaud& Izopet, Jacques& Kamar, Nassim. Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of Transplantation. 2015. Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1070432
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1070432